Value
7.7/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 8.0 |
| EV/EBITDA | 5.9 |
| Fwd P/E | 9.2 |
| Analyst target | 6.0 |
- ▸Forward P/E: 10.3x
- ▸Attractively valued
RIGL · Why this verdict
Why Rigel Pharmaceuticals (RIGL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Rigel Pharmaceuticals is a profitable biotech with 127% ROE and 31% analyst upside, but revenue is down 23%, earnings quality is flagged with negative free cash flow, and earnings are expected to fall about 71% from a peak.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Rigel earns an excellent 127% ROE and ranks near the top of peers on quality, with a forward P/E of 9.7x. Quality breakdown | ROE stays above 50% and the forward P/E stays below 12x over the next 12 months. | →Stable |
| CounterThe 127% ROE is inflated by a small equity base, and the forward P/E is about 3.4x the trailing multiple, a sign that trailing earnings overstate recurring profit. | ||
Revenue is declining 23% and earnings are expected to fall about 71% from a peak, with growth scoring 0.0/10. Growth breakdown | Quarterly revenue stabilizes above the latest $78.7M and the next-quarter estimate of $80.1M is met. | →Stable |
| CounterRevenue is lumpy (from $101.7M in June 2025 to $58.8M in March 2026), so a big drop may recur and push earnings sharply lower. | ||
Revenue depends heavily on TAVALISSE, flagged as a high product concentration risk. Bear case | TAVALISSE sales hold up and new products add diversification over the next 12 months. | ↓Deteriorating |
| CounterCompetition, pricing pressure or a regulatory setback on one product would hit most of the revenue with no other product to offset it. | ||
The analyst target of $54.81 implies 13.9% upside from $48.13, with reward-to-risk of 1.85 against 7.5% downside to the stop. Upside pct | Price moves toward the analyst target if quarterly results stay profitable. | →Stable |
| CounterCoverage is light with 5 analysts and the target is haircut by 13%, so limited upside may not compensate for the earnings risk. | ||
Earnings quality is flagged as a red flag, with free cash flow at -10% of net income and a Rule of 40 reading of -34, and recent EPS shows 2 beats and 2 misses. Catalyst breakdown | Free cash flow turns positive and exceeds 50% of net income within 12 months. | →Stable |
| CounterNegative cash conversion while reporting profits suggests accounting earnings may not reflect cash generation, and the next report is 10 days away. | ||
Rigel earns an excellent 127% ROE and ranks near the top of peers on quality, with a forward P/E of 9.7x.
→StableQuality breakdown
- Expectation
- ROE stays above 50% and the forward P/E stays below 12x over the next 12 months.
CounterThe 127% ROE is inflated by a small equity base, and the forward P/E is about 3.4x the trailing multiple, a sign that trailing earnings overstate recurring profit.
Revenue is declining 23% and earnings are expected to fall about 71% from a peak, with growth scoring 0.0/10.
→StableGrowth breakdown
- Expectation
- Quarterly revenue stabilizes above the latest $78.7M and the next-quarter estimate of $80.1M is met.
CounterRevenue is lumpy (from $101.7M in June 2025 to $58.8M in March 2026), so a big drop may recur and push earnings sharply lower.
Revenue depends heavily on TAVALISSE, flagged as a high product concentration risk.
↓DeterioratingBear case
- Expectation
- TAVALISSE sales hold up and new products add diversification over the next 12 months.
CounterCompetition, pricing pressure or a regulatory setback on one product would hit most of the revenue with no other product to offset it.
The analyst target of $54.81 implies 13.9% upside from $48.13, with reward-to-risk of 1.85 against 7.5% downside to the stop.
→StableUpside pct
- Expectation
- Price moves toward the analyst target if quarterly results stay profitable.
CounterCoverage is light with 5 analysts and the target is haircut by 13%, so limited upside may not compensate for the earnings risk.
Earnings quality is flagged as a red flag, with free cash flow at -10% of net income and a Rule of 40 reading of -34, and recent EPS shows 2 beats and 2 misses.
→StableCatalyst breakdown
- Expectation
- Free cash flow turns positive and exceeds 50% of net income within 12 months.
CounterNegative cash conversion while reporting profits suggests accounting earnings may not reflect cash generation, and the next report is 10 days away.
Per-dimension breakdown
Quality
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Current ratio | 6.8 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 127%
- ▸Earnings quality RED FLAG: -10% FCF/NI
- ▸Rule of 40: -34 (fail)
Growth
0.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 0.0 |
- ▸Declining revenue: -23%
Momentum
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.8 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.5 |
| Price target | 8.1 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 24%
Insider
6.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 7.2 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
6.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.8 |
| quality rank | 9.9 |
| growth rank | 2.9 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.1 |
| support resistance | 1.0 |
| 52w position | 9.4 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.0 |
| days to cover | 0.0 |
| volatility | 4.7 |
| put call | 1.7 |
| implied vol | 0.0 |
| beta | 6.3 |
| debt equity | 9.6 |
- ▸Short squeeze setup: 15% short, quality 7.5
- ▸Elevated put/call: 1.75
- ▸High IV: 80%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 5 days
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier -2 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=-2Passed (5)
- MOMENTUM:7.7>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:0.7<1.5@spot
- EARNINGS_PROXIMITY:5d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.74
Upside
+8.0%
Downside
10.9%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.7>=5.5. Top dim: Value at 7.7; weakest: Growth at 0.0. No conviction either direction.
The strongest dimensions are Value at 7.7, Momentum at 7.7, and Quality at 7.1; the weakest are Growth at 0.0, Technical at 3.5, and Risk (lower is worse) at 4.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.74 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Returns Profitable Biotech
Trip ifROE falls below 50% from the current 127%.
- P2Declining Revenue And Earnings Outlook
Trip ifQuarterly revenue falls below $60M for 2 consecutive quarters.
- P3Single Product Concentration
Trip ifTAVALISSE share of total revenue exceeds 90%.
- P4Analyst Upside To Target
Trip ifPrice falls below the $44.76 stop level.
- P5Earnings Quality Red Flag
Trip ifFree cash flow to net income ratio stays below 0% for 2 consecutive quarters.